This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119115 (2022)
Related article
Lokeshwar, S. D., Klaassen, Z. & Saad, F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat. Rev. Urol. 18, 433–442 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fenner, A. Darolutamide combo is an ARASENSible option for mHSPC. Nat Rev Urol 19, 194 (2022). https://doi.org/10.1038/s41585-022-00579-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00579-0
This article is cited by
-
Androgen receptor pathway inhibitor combination in prostate cancer
Nature Reviews Urology (2022)